1-cyclopropyl-3,3-dimethylbutan-1-one | 34640-61-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclopropyl-3,3-dimethylbutan-1-one
• 英文别名: Dimethyl-2,2-cyclopropyl-4-butanon-4
• CAS: 34640-61-4
• 化学式: C₉H₁₆O
• mdl: MFCD20335976
• 分子量: 140.225
• InChiKey: GWKJLMYWFKWKSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-((E)-1-Cyclopropyl-3,3-dimethyl-but-1-enyl)-[1,3,2]dioxaborinane 在 双氧水 、 sodium acetate 作用下， 以 四氢呋喃 为溶剂， 以73%的产率得到1-cyclopropyl-3,3-dimethylbutan-1-one
  参考文献：
  名称：

  （E）-B -2-（1-环丙基-1-烯基）-1,3,2-二氧杂硼烷酮的高度非对映选择性合成。分离并氧化为烷基环丙基酮

  摘要：

  开发了一种基于Z -1-溴-1-烯基硼酸酯的方便，新颖的烷基环丙基酮的合成方法。可从文献程序容易获得的α-溴-（（Z）-1-烯基硼酸酯）与环丙基溴化镁在四氢呋喃中顺利进行反应，以提供相应的“配合物”配合物。这些“酸酯”配合物经过分子内亲核取代反应，以良好的分离产率（68-82％）首次提供了相应的含环丙基丙基的（E）-1-链烯基硼酸酯。这些中间体中存在的碳骨架可通过用过氧化氢和乙酸钠氧化确认，以良好的收率（72-85％）得到相应的烷基环丙基酮。

  DOI：

  10.1016/s0040-4039(03)01841-0

文献信息

• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• [EN] 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES<br/>[FR] DERIVES 4-(3,3-DIHALO-ALLYLOXY)PHENOXYALKYLE
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2004002943A1

  公开（公告）日：2004-01-08

  Compounds of formula (I), wherein A1, A2 and A3 are each independently of the others a bond or a C1-C6alkylene bridge; A4 is a C1-C6alkylene bridge; Di s CH or N; W is, for example, O, NR7 or S; T is, for example, a bond, O, NH or NR7; Q is O, NR7, S, SO or SO2; Y is O, NR7, S, SO, or SO2; X1 and X2 are each independently of the other fluorine, chlorine or bromine; R1, R2 and R3 ar, for example, H, halogen, CN, nitro, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylcarbonyl or C2-C6alkenyl; R4 is, for example, H, halogen, CN, nitro or C1-C6alkyl; R5 and R6 are, for example, H, CN, OH, C1-C6alkyl, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C1-C6 haloalky, C1-C6alkoxy or C1-C6haloalkoxy; R7 is H, C1-C6alkyl, C1-C6alkoxyalkyl or C1-C6alkylcarbonyl; k, when D is nitrogen, is 1, 2 or 3; or, when D is CH, is 1, 2, 3 or 4; and m is 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds or an agrochemically acceptable salt thereof, a process for the preparation of those compositions and their use, plant propagation material treated with those compositions, and a method of controlling pests.

  化学式为（I）的化合物，其中A1、A2和A3各自独立地为键或C1-C6烷基桥；A4为C1-C6烷基桥；Di为CH或N；W为例如O、NR7或S；T为例如键、O、NH或NR7；Q为O、NR7、S、SO或SO2；Y为O、NR7、S、SO或SO2；X1和X2各自独立地为氟、氯或溴；R1、R2和R3例如为H、卤素、CN、硝基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷基羰基或C2-C6烯基；R4例如为H、卤素、CN、硝基或C1-C6烷基；R5和R6例如为H、CN、OH、C1-C6烷基、C3-C8环烷基、C3-C8环烷基-C1-C6烷基、C1-C6卤代烷氧基或C1-C6烷氧基；R7为H、C1-C6烷基、C1-C6烷氧基烷基或C1-C6烷基羰基；当D为氮时，k为1、2或3；或当D为CH时，k为1、2、3或4；m为1或2；适用时，它们的可能的E/Z异构体、E/Z异构体混合物和/或互变异构体，均为自由形式或盐形式，制备这些化合物的方法及其用途，所述活性成分被选自这些化合物或其农药学上可接受的盐的杀虫剂组合物，制备这些组合物的方法及其用途，用这些组合物处理的植物繁殖材料，以及控制害虫的方法。
• Iodocyclization/base-induced hydrodeiodination reaction of 5-substituted 4-alkenols. The influence of substituent on the stereoselective pathway
  作者：Claudio Paolucci、Paolo Righi

  DOI：10.1016/j.tet.2007.09.074

  日期：2007.12

  erythro-2-(1-iodo-2,2-dimetylpropyl)tetrahydrofuran with high stereoselectivity. The threo isomer gave clean formation of 6-tert-butyl-3,4-dihydro-2H-pyran by base-induced ring expansion, while erythro isomer underwent a base-induced ring contraction to 1-cyclopropyl-3,3-dimethylbutan-1-one. Moreover, (Z)- and (E)-5-cyclopropylpent-4-en-1-ol underwent a 6-endo-iodocyclization to threo- and erythro-2-cyclopropyl

  （Z）-和（E）-5 - n-烷基取代的4-烯-1-醇的亲电碘环化反应，然后进行碱诱导的加氢碘化反应，分别在高浓度下分别立体地生成（Z）-和（E）-烷基二氢呋喃屈服。（Z）-和（E）-6,6-二甲基庚-4-en-1-ol观察到完全不同的结果：它们的碘环化分别提供了苏-和赤--2- （1-碘-2,2） -二甲基丙基）四氢呋喃具有高的立体选择性。的苏式异构体，得到纯地层6-叔丁基-3,4-二氢-2 ħ-吡喃通过碱诱导的环膨胀，而赤型异构体经历了碱诱导的环收缩为1-环丙基-3,3-二甲基丁烷-1-酮。此外，（Ž） -和（Ë）-5- cyclopropylpent -4-烯-1-醇进行了6-内-iodocyclization到苏型-和赤-2-环丙基-3- iodotetrahydro-2 ħ吡喃，分别在相同的基本处理下，以立体选择性的方式得到两个异构的6-环丙基二氢-2 H-吡喃。
• BIOLOGICALLY ACTIVE AMIDES
  申请人：Peterson John Matthew

  公开号：US20110230497A1

  公开（公告）日：2011-09-22

  The present invention is directed to biologically active amides which are ligands at the NPY Y5 receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from certain disorders which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, this invention also provides uses of a compound of the invention for the manufacture of a medicament for treating a subject suffering from certain disorders.

  本发明涉及生物活性酰胺，其是NPY Y5受体的配体。该发明还提供了一种制药组合物，包括本发明化合物的治疗有效量和药学可接受载体。本发明还提供了治疗患有某些疾病的受试者的方法，包括向受试者投予本发明化合物的量。此外，本发明还提供了一种利用本发明化合物制造治疗患有某些疾病的受试者的药物的用途。
• N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20160024097A1

  公开（公告）日：2016-01-28

  The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I中的N-(4-(氮杂吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3在权利要求中指定了它们的含义。式I化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶亚型1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。此外，本发明还涉及制备式I化合物的方法，它们作为药物的用途以及包含它们的制剂。